Biotechnology News CEFAZOLIN Search

BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login

Search Results

Documents 1-5 out of 5 found

Current Search: cefazolin: 5

Surgical Site Infection in Liver Transplant Recipients: Impact of the Type of Perioperative Prophylaxis
Surgical site infection (SSI) is an important cause of morbidity after orthotopic liver transplantation (OLT).

Perioperative antibiotic prophylaxis is one of the main modifiable risk factors.

We prospectively investigated the...

Transplantation: Jun 25 2008 4:40AM
Matching: cefazolin

Find similar documents

Risk factors for infection after liver transplantation identified
NEW YORK (Reuters Health) - In a new study, Spanish researchers have identified several factors that are predictive of surgical site infections (SSIs) following orthotopic liver transplantation.

SSIs are a common problem after liver...

Clinical Lab Products: Jun 15 2008 9:12AM
Matching: cefazolin

Find similar documents

Researchers Pinpoint Risk Factors for Infections Post-Liver Transplantation
my personal edition> organ transplantation > news E-Mail this DGNews to a colleague DGNews HOBOKEN, NJ -- June 6, 2008 -- Nearly 9% of patients who recently underwent liver transplantation suffered a subsequent surgical site...

Doctors Guide: Jun 6 2008 10:12PM
Matching: cefazolin

Find similar documents

Dragon realigns business segment into 2 divisions
Dragon Pharmaceutical Inc, a leading international pharmaceutical company, said that beginning with the first quarter of 2008, the company has realigned its business segments into two divisions: Cephalosporin and Penicillin.

This...

PharmaBiz: Apr 29 2008 12:13PM
Matching: cefazolin

Find similar documents

Dragon Pharmaceutical Announces Strategic Realignment of its Business Segments into Two Divisions: Cephalospor
- Dragon Pharmaceutical Inc.

('Dragon' or the 'Company' TSX: DDD; OTCBB: DRUG; BBSE: DRP), a leading international pharmaceutical company, today announced that beginning with the first quarter of 2008, the Company has realigned its...

Pharma Live: Apr 22 2008 8:23PM
Matching: cefazolin

Find similar documents

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright � 1997-2008 - BioPortfolio Limited.